CD274 and hepatocellular carcinoma: In addition, a recent clinical trial (NCT03434379) in patients with unresectable hepatocellular carcinoma (HCC) demonstrated atezolizumab (anti-PD-L1) combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib [111], leading to recent FDA approval for the treatment of people with unresectable or metastatic HCC who have not received prior systemic therapy.